Robert Julian Binder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Julian Binder has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Abigail L. Sedlacek
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
51 shared publications - Devanshi A. Nayak
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
47 shared publications - Simon Charles Watkins
Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA
47 shared publications - Anthony R. Cillo
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
46 shared publications Sudesh Pawaria
Department of Medicine, University of Massachusetts Medical Center, Worcester, MA 01655
7 shared publicationsAbigail L. Sedlacek
Department of Immunology, University of Pittsburgh
5 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy
Despite substantial treatment improvements, the 5-year survival rate for metastatic osteosarcoma (OS) is still as low as 20%. Immunocompetent genetic mouse models of OS have been introduced, enabling in vivo OS studies. Here, we present the ROCCIA mouse, a quintuple-mutant extension of these models that develops multifluorescent OS tumors, allowing distinct fluorescently labeled OS cell populations to be identified and traced both within tumors and in the circulation. In addition, this model enables postnatal inactivation of the p53 and Rb1 genes, thus resembling development and progression of OS in humans. Using this model, we show that osterix ( Osx )–expressing fluorescent tumor cells appear in circulation upon OS development and predominate in lung metastases, thus representing a potential target for future therapies. We also show that the immunological landscape of this model’s tumor microenvironment mimics the previously described human OS microenvironment. Therefore, this immunocompetent, quintuple mutant, multifluorescent mouse model represents a powerful resource to analyze OS tumor development and metastasis in real time and to test translational therapies.
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Open AccessAn immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy
Despite substantial treatment improvements, the 5-year survival rate for metastatic osteosarcoma (OS) is still as low as 20%. Immunocompetent genetic mouse models of OS have been introduced, enabling in vivo OS studies. Here, we present the ROCCIA mouse, a quintuple-mutant extension of these models that develops multifluorescent OS tumors, allowing distinct fluorescently labeled OS cell populations to be identified and traced both within tumors and in the circulation. In addition, this model enables postnatal inactivation of the p53 and Rb1 genes, thus resembling development and progression of OS in humans. Using this model, we show that osterix ( Osx )–expressing fluorescent tumor cells appear in circulation upon OS development and predominate in lung metastases, thus representing a potential target for future therapies. We also show that the immunological landscape of this model’s tumor microenvironment mimics the previously described human OS microenvironment. Therefore, this immunocompetent, quintuple mutant, multifluorescent mouse model represents a powerful resource to analyze OS tumor development and metastasis in real time and to test translational therapies.
- 1 October 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (10)
The second face of HSPs: a review of key functions in the immune system
Heat shock proteins (HSPs) are an abundant class of proteins well known for their functions in protein folding and molecular chaperoning within all compartments of a cell. These functions are fundamental in all single and multicellular organisms, and so HSPs have remained relatively conserved in structure throughout evolution. The ability of select members of the HSP family to chaperone peptides and molecules associated with host defense against internal and external threats means that the HSPs have an important role in the immune system. We discuss the roles of HSPs that are integral to pathways of Ag transfer between cells, Ag presentation by MHC molecules, stimulation of innate immune responses, expression of innate immune receptors, cancer and viral immunology, and autoimmunity. The ample appreciation for these roles of HSPs in the immune system has led to the development and testing of HSPs both as therapeutics and targets for various diseases. These discoveries have been made with only a handful of the HSPs, suggesting a significant number of immune functions of other HSPs remain uncharted.
- 1 October 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (10)
The second face of HSPs: a review of key functions in the immune system
Heat shock proteins (HSPs) are an abundant class of proteins well known for their functions in protein folding and molecular chaperoning within all compartments of a cell. These functions are fundamental in all single and multicellular organisms, and so HSPs have remained relatively conserved in structure throughout evolution. The ability of select members of the HSP family to chaperone peptides and molecules associated with host defense against internal and external threats means that the HSPs have an important role in the immune system. We discuss the roles of HSPs that are integral to pathways of Ag transfer between cells, Ag presentation by MHC molecules, stimulation of innate immune responses, expression of innate immune receptors, cancer and viral immunology, and autoimmunity. The ample appreciation for these roles of HSPs in the immune system has led to the development and testing of HSPs both as therapeutics and targets for various diseases. These discoveries have been made with only a handful of the HSPs, suggesting a significant number of immune functions of other HSPs remain uncharted.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 2. Validation of CD91 deletion in cDC1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 2. Validation of CD91 deletion in cDC1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 14. Antigen presenting cells within sorted and adoptively transferred cells. Lymph nodes from mice challenged with gp96-EGFP+ tumor were processed and sorted on live CD19- CD3- CD45+ CD11c+/- CD11b+/- gp96+ as shown in Supplementary figure 7A. Sorted cells were further stained using additional markers to further subset the sorted populations of cells transferred in Fig. 5.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 14. Antigen presenting cells within sorted and adoptively transferred cells. Lymph nodes from mice challenged with gp96-EGFP+ tumor were processed and sorted on live CD19- CD3- CD45+ CD11c+/- CD11b+/- gp96+ as shown in Supplementary figure 7A. Sorted cells were further stained using additional markers to further subset the sorted populations of cells transferred in Fig. 5.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S16 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary figure 16. Single-cell analysis to compare APC subsets.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary figure 16. Single-cell analysis to compare APC subsets.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 13. Transfer of gp96-EGFP by CD11c+ CD11b- donors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 13. Transfer of gp96-EGFP by CD11c+ CD11b- donors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 6. cDC1-specific deletion of CD91 affects frequency and quality of CD8+ T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary Figure 6. cDC1-specific deletion of CD91 affects frequency and quality of CD8+ T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Table S4 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Table S4 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary figure 15. Separation of gp96-mediated anti-tumor immune function within APC subsets.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Supplementary figure 15. Separation of gp96-mediated anti-tumor immune function within APC subsets.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Table S3 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors
Table S3 from CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors